Multivariate Biomarker Study for Sarcopenia in Heart Failure (NCT06217640) | Clinical Trial Compass
Active ā Not RecruitingNot Applicable
Multivariate Biomarker Study for Sarcopenia in Heart Failure
United Kingdom80 participantsStarted 2023-08-01
Plain-language summary
In the United Kingdom, heart failure (HF) affects about 900,000 people with 60,000 new cases annually. Up to 60% of people living with HF also experience sarcopenia, known as loss of muscle mass and strength. Sarcopenia contributes significantly to low physical capacity and exercise intolerance and worsens the prognosis of the disease and quality of life.
In comparison to primary sarcopenia (age-related sarcopenia), secondary sarcopenia occurs if other factors, including malignancy or organ failure, are evident in addition to aging. Secondary sarcopenia is highly common in patients with heart failure (Sarc-HF) (prevalence is 35%-69%), and has a significantly negative impact on exercise capacity, weight-adjusted peak maximal oxygen consumption, left ventricular function, and re-hospitalization rates and mortality.
In this integrated study of NHS patients with HF, the investigators aim is to identify the underlying mechanisms of muscle weakness in HF utilizing including body composition, circulating metabolites (metabolic profile), and functional tests for (1) early detection of otherwise subclinical HF, (2) diagnostic assessment of clinically manifest HF-sarcopenia, (3) the risk stratification of subjects with a suspected or confirmed diagnosis, and (4) selection of an appropriate therapeutic intervention.
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Clinically diagnosed HF regardless of ejection fraction rate (both HFrEF and HFpEF).
ā. Age 50 years and older.
ā. BMI more than 18 and less than 30 kg/m\^2.
ā. Must be on optimal medical treatment for three months prior to inclusion.
ā. Do not have contraindications to providing a blood sample.
ā. Sufficient mental capacity to consent as determined by the researchers.
ā. Able to walk with or without a walker for at least 16 m.
ā. No objection to the researchers contacting their general practitioner and neurologist.
Exclusion criteria
ā. Receiving treatment with antibiotics, probiotics, or fish oil during the last 3 months prior to inclusion.
ā. Major comorbidities (i.e., cancer, Alzheimer's, type 2 diabetes, chronic kidney disease).